Skip to main content
. Author manuscript; available in PMC: 2019 Mar 7.
Published in final edited form as: Knee. 2018 Mar 7;25(2):296–305. doi: 10.1016/j.knee.2018.01.009

Table 3.

Influence of Time Frames and Covariates on C2C:CPII collected at the Six-Month Follow-Up Exam and Days Between Injury and Surgery

Covariate R2 (Unstandardized β) Between Covariate and C2C:CPII ΔR2 (Unstandardized β) Between Injury and Surgery and C2C:CPII after accounting for the covariate
Days Between Injury and Six-Month Follow-up 0.025 (0.0002) 0.194 (0.001) *
Days Between ACLR and Six-Month Follow-up 0.023 (0.0002) 0.196 (0.001) *
Body Mass Index 0.001 (0.0002) 0.213 (0.001) *
Sex 0.258 (−0.023) * 0.207 (0.001) *
Age 0.029 (0.001) 0.185 (0.001) *
History of previous ACLR 0.011 (−0.006) 0.219 (0.001) *
Concomitant Meniscal Injury 0.056 (−0.011) 0.201 (0.001) *
Concomitant Chondral Injury 0.051 (−0.011) 0.165 (0.001)
KOOS Symptoms at Initial Presentation 0.001 (0.00003) 0.223 (0.001) *
KOOS Pain at Initial Presentation 0.012 (−0.0001) 0.202 (0.001) *
KOOS Daily Living at Initial Presentation 0.033 (−0.0002) 0.180 (0.001) *
KOOS Sports at Initial Presentation 0.035 (0.0001) 0.266 (0.001) *
KOOS Quality of Life at Initial Presentation 0.061 (−0.0003) 0.158 (0.001)
Tegner Activity Scale at Six-Month Follow-Up 0.013 (−0.0006) 0.190 (0.001)

ACLR – Anterior Cruciate Ligament Reconstruction, KOOS – Knee Osteoarthritis and Outcome Score, C2C – Type-II Collagen Cleavage Product, CPII – C-Propeptide of Type-II Collagen Procollagen, ARGS – Alanin-Arginine-Glycine-Serine, IL-6 – Interleukin-6, MMP-3 – Matrix Metalloproteinase-3

*

Significant F Change at p ≤ 0.05